Abstract: Objective To investigate the value of the aspartate aminotransferase to lymphocyte ratio (ALRI) in the prognosis evaluation of primary liver cancer(PLC) with portal vein tumor thrombosis(PVTT) patients before transcatheter arterial chemoembolization (TACE). Methods A total of 175 patients with PLC and PVTT who received TACE treatment in Guangxi Medical University Cancer Hospital from June 2013 to June 2018 were selected. The optimal critical value of ALRI was determined by the time-dependent ROC curve, the independent predictors of overall survival(OS) were analyzed by Cox regression model, and the survival rate was calculated by Kaplan-Meier method. Results The ROC curve showed that the optimal clinical value of ALRI was 49.37, and the corresponding AUC was 0.71. Kaplan Meier analysis showed that the OS of patients with ALRI>49.37 was shorter than that of patients with ALRI≤49.37(P=0.003). Cox regression analysis showed that ALRI>49.37, more than one TACE treatment, Child-Pugh grade B, and prothrombin time≥13 s were among the independent risk factors for OS in PVTT patients after TACE (all P<0.05). Conclusion ALRI>49.37 before TACE is an independent risk factor for OS in patients with PLC-PVTT.

Key words: Primary liver cancer, Portal vein tumor thrombosis, Transcatheter arterial chemoembolization, Aspartate aminotrans-ferase, Lymphocyte, Prognosis